Urinary incontinence historical perspective: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Urinary incontinence}} {{CMG}}; {{NN}} ==Overview== == Historical Perspective== * urinary incontinence was first described by ancient Egyptians in 1500 BC th...") |
No edit summary |
||
Line 18: | Line 18: | ||
*In 1929, the modern [[urethral]] [[catheter]] was first developed by Frederic Foley to control postoperative [[bleeding]] after [[suprapubic]] prostatectomies. | *In 1929, the modern [[urethral]] [[catheter]] was first developed by Frederic Foley to control postoperative [[bleeding]] after [[suprapubic]] prostatectomies. | ||
*In 1962, [[reflexive therapy]] was introduced by T. Dickson for [[ urge incontinence]] secondary to [[neurogenic bladder]]. <ref name="pmid29053886">{{cite journal| author=Chong JT, Simma-Chiang V| title=A historical perspective and evolution of the treatment of male urinary incontinence. | journal=Neurourol Urodyn | year= 2018 | volume= 37 | issue= 3 | pages= 1169-1175 | pmid=29053886 | doi=10.1002/nau.23429 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29053886 }} </ref> | *In 1962, [[reflexive therapy]] was introduced by T. Dickson for [[ urge incontinence]] secondary to [[neurogenic bladder]]. <ref name="pmid29053886">{{cite journal| author=Chong JT, Simma-Chiang V| title=A historical perspective and evolution of the treatment of male urinary incontinence. | journal=Neurourol Urodyn | year= 2018 | volume= 37 | issue= 3 | pages= 1169-1175 | pmid=29053886 | doi=10.1002/nau.23429 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29053886 }} </ref> | ||
*In the late 19th , Robert Gersuny treated [[urinary incontinence]] with injecting paraffin into the [[urethra]] and [[periurethral]] areas. <ref name="pmid29053886">{{cite journal| author=Chong JT, Simma-Chiang V| title=A historical perspective and evolution of the treatment of male urinary incontinence. | journal=Neurourol Urodyn | year= 2018 | volume= 37 | issue= 3 | pages= 1169-1175 | pmid=29053886 | doi=10.1002/nau.23429 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29053886 }} </ref><ref name="pmid10940713">{{cite journal| author=Schultheiss D, Höfner K, Oelke M, Grünewald V, Jonas U| title=Historical aspects of the treatment of urinary incontinence. | journal=Eur Urol | year= 2000 | volume= 38 | issue= 3 | pages= 352-62 | pmid=10940713 | doi=10.1159/000020306 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10940713 }} </ref> | |||
*Others injectable bulking agents have been found for curing the [[urinary incontinence]], including <ref name="pmid929773">{{cite journal| author=Heer H| title=[Treatment of Urinary incontinence by Teflon injection (author's transl)]. | journal=Urol Int | year= 1977 | volume= 32 | issue= 4 | pages= 295-302 | pmid=929773 | doi=10.1159/000280145 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=929773 }} </ref> <ref name="pmid15332628">{{cite journal| author=Jordan O, Doelker E, Defabiani N, Caviezel A, Iselin C| title=Novel injectable urethral bulking agents for the treatment of urinary incontinence. | journal=J Mater Sci Mater Med | year= 2004 | volume= 15 | issue= 4 | pages= 519-22 | pmid=15332628 | doi=10.1023/b:jmsm.0000021131.15283.18 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15332628 }} </ref> <ref name="pmid22435469">{{cite journal| author=Yamamoto T, Gotoh M, Kato M, Majima T, Toriyama K, Kamei Y | display-authors=etal| title=Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases. | journal=Int J Urol | year= 2012 | volume= 19 | issue= 7 | pages= 652-9 | pmid=22435469 | doi=10.1111/j.1442-2042.2012.02999.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22435469 }} </ref> <ref name="pmid15247778">{{cite journal| author=Thornton AJ, Alsberg E, Hill EE, Mooney DJ| title=Shape retaining injectable hydrogels for minimally invasive bulking. | journal=J Urol | year= 2004 | volume= 172 | issue= 2 | pages= 763-8 | pmid=15247778 | doi=10.1097/01.ju.0000130466.84214.f7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15247778 }} </ref> | |||
**[[Teflon]] | |||
**[[collagen]] | |||
**autologous [[adipose tissue]] | |||
**cross-linked [[silicone]] gels | |||
*Since 20th century, new [[urethral]] injection therapies such as [[stem cell]] therapy have been developed for treating [[urinary incontinence]]. | |||
*In 1988, [[Botulinum toxin]] A ([[Botox]]) was introduced for [[detrusor]] [[sphincter]] disorder secondary to [[spinal cord injury]]. <ref name="pmid3361663">{{cite journal| author=Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD| title=Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. | journal=J Urol | year= 1988 | volume= 139 | issue= 5 | pages= 919-22 | pmid=3361663 | doi=10.1016/s0022-5347(17)42717-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3361663 }} </ref> | |||
*After FDA approval of [[Botox]] injection in 2011, it has been used for treating [[urinary incontinence]] in [[neurogenic]] [[detrusor overactivity]] and patients who cannot tolerate [[anticholinergic]] [[medications]]. <ref name="pmid23941788">{{cite journal| author=Linsenmeyer TA| title=Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. | journal=J Spinal Cord Med | year= 2013 | volume= 36 | issue= 5 | pages= 402-19 | pmid=23941788 | doi=10.1179/2045772313Y.0000000116 | pmc=3739890 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23941788 }} </ref> | |||
===Development of Treatment Strategies=== | ===Development of Treatment Strategies=== | ||
==References== | ==References== |
Revision as of 12:32, 30 September 2020
Urinary incontinence Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Urinary incontinence historical perspective On the Web |
American Roentgen Ray Society Images of Urinary incontinence historical perspective |
Risk calculators and risk factors for Urinary incontinence historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Nasrin Nikravangolsefid, MD-MPH [2]
Overview
Historical Perspective
- urinary incontinence was first described by ancient Egyptians in 1500 BC that resulted from spinal cord injury. [1]
- Leonardo da Vinci (1452-1519) described the internal sphincter at the neck of the bladder in his drawings.[2]
- In 1564, several portable urinals was developed by Ambros Pare to treat urinary incontinence in males. [3]
- In the 1600s, the condom catheter with pig bladder was first designed by Wilhem Hildanus. [3]
- In 1747, a perineal bulbar urethral compression belt was first innovated by Lorenz Heister. [1]
Landmark Events in the Development of Treatment Strategies
- In the 17-19th centuries, some natural medications with anticholinergic and antidiuretic effects including opium, strychnine, and atropine were introduced as a therapeutic strategy for urge incontinence. [1]
- In 1858, carbonic acid with chloroform was used by J.Rhodes to treat nocturnal incontinence in an old man. [4]
- In 1929, the modern urethral catheter was first developed by Frederic Foley to control postoperative bleeding after suprapubic prostatectomies.
- In 1962, reflexive therapy was introduced by T. Dickson for urge incontinence secondary to neurogenic bladder. [1]
- In the late 19th , Robert Gersuny treated urinary incontinence with injecting paraffin into the urethra and periurethral areas. [1][3]
- Others injectable bulking agents have been found for curing the urinary incontinence, including [5] [6] [7] [8]
- Teflon
- collagen
- autologous adipose tissue
- cross-linked silicone gels
- Since 20th century, new urethral injection therapies such as stem cell therapy have been developed for treating urinary incontinence.
- In 1988, Botulinum toxin A (Botox) was introduced for detrusor sphincter disorder secondary to spinal cord injury. [9]
- After FDA approval of Botox injection in 2011, it has been used for treating urinary incontinence in neurogenic detrusor overactivity and patients who cannot tolerate anticholinergic medications. [10]
Development of Treatment Strategies
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Chong JT, Simma-Chiang V (2018). "A historical perspective and evolution of the treatment of male urinary incontinence". Neurourol Urodyn. 37 (3): 1169–1175. doi:10.1002/nau.23429. PMID 29053886.
- ↑ Schultheiss D, Grünewald V, Jonas U (1999). "Urodynamics in the anatomical work of Leonardo da Vinci (1452-1519)". World J Urol. 17 (3): 137–43. doi:10.1007/s003450050121. PMID 10418086.
- ↑ 3.0 3.1 3.2 Schultheiss D, Höfner K, Oelke M, Grünewald V, Jonas U (2000). "Historical aspects of the treatment of urinary incontinence". Eur Urol. 38 (3): 352–62. doi:10.1159/000020306. PMID 10940713.
- ↑ "Incontinence of Urine Treated by the Local Application of Carbonic Acid Gas with Chloroform".
- ↑ Heer H (1977). "[Treatment of Urinary incontinence by Teflon injection (author's transl)]". Urol Int. 32 (4): 295–302. doi:10.1159/000280145. PMID 929773.
- ↑ Jordan O, Doelker E, Defabiani N, Caviezel A, Iselin C (2004). "Novel injectable urethral bulking agents for the treatment of urinary incontinence". J Mater Sci Mater Med. 15 (4): 519–22. doi:10.1023/b:jmsm.0000021131.15283.18. PMID 15332628.
- ↑ Yamamoto T, Gotoh M, Kato M, Majima T, Toriyama K, Kamei Y; et al. (2012). "Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases". Int J Urol. 19 (7): 652–9. doi:10.1111/j.1442-2042.2012.02999.x. PMID 22435469.
- ↑ Thornton AJ, Alsberg E, Hill EE, Mooney DJ (2004). "Shape retaining injectable hydrogels for minimally invasive bulking". J Urol. 172 (2): 763–8. doi:10.1097/01.ju.0000130466.84214.f7. PMID 15247778.
- ↑ Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988). "Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients". J Urol. 139 (5): 919–22. doi:10.1016/s0022-5347(17)42717-0. PMID 3361663.
- ↑ Linsenmeyer TA (2013). "Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review". J Spinal Cord Med. 36 (5): 402–19. doi:10.1179/2045772313Y.0000000116. PMC 3739890. PMID 23941788.